217 related articles for article (PubMed ID: 27458154)
21. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
[TBL] [Abstract][Full Text] [Related]
22. Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice.
Lesma E; Eloisa C; Isaia E; Grande V; Ancona S; Orpianesi E; Di Giulio AM; Gorio A
Am J Pathol; 2012 Sep; 181(3):947-60. PubMed ID: 22770663
[TBL] [Abstract][Full Text] [Related]
23. Lymphangioleiomyomatosis and TSC2-/- cells.
Darling TN; Pacheco-Rodriguez G; Gorio A; Lesma E; Walker C; Moss J
Lymphat Res Biol; 2010 Mar; 8(1):59-69. PubMed ID: 20235888
[TBL] [Abstract][Full Text] [Related]
24. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
25. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
Tyryshkin A; Bhattacharya A; Eissa NT
Cancer Res; 2014 Apr; 74(7):1996-2005. PubMed ID: 24691995
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis.
Feng Y; Mischler WJ; Gurung AC; Kavanagh TR; Androsov G; Sadow PM; Herbert ZT; Priolo C
Cancer Res; 2020 Jul; 80(13):2751-2763. PubMed ID: 32393662
[TBL] [Abstract][Full Text] [Related]
27. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
28. Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Guo CJ; Abramova E; Golden TN; Sims M; James ML; Beers MF; Gow AJ; Krymskaya VP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):96-104. PubMed ID: 25474372
[TBL] [Abstract][Full Text] [Related]
29. Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
Cui Y; Steagall WK; Lamattina AM; Pacheco-Rodriguez G; Stylianou M; Kidambi P; Stump B; Golzarri F; Rosas IO; Priolo C; Henske EP; Moss J; El-Chemaly S
Cancer Res; 2017 Mar; 77(6):1492-1502. PubMed ID: 28202529
[TBL] [Abstract][Full Text] [Related]
30. Role of Prolactin Receptors in Lymphangioleiomyomatosis.
Alkharusi A; Lesma E; Ancona S; Chiaramonte E; Nyström T; Gorio A; Norstedt G
PLoS One; 2016; 11(1):e0146653. PubMed ID: 26765535
[TBL] [Abstract][Full Text] [Related]
31. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
32. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma.
Clements D; Markwick LJ; Puri N; Johnson SR
J Immunol; 2010 Aug; 185(3):1812-21. PubMed ID: 20585037
[TBL] [Abstract][Full Text] [Related]
33. Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
Li C; Liu X; Liu Y; Zhang E; Medepalli K; Masuda K; Li N; Wikenheiser-Brokamp KA; Osterburg A; Borchers MT; Kopras EJ; Plas DR; Sun J; Franz DN; Capal JK; Mays M; Sun Y; Kwiatkowski DJ; Alayev A; Holz MK; Krueger DA; Siroky BJ; Yu JJ
Mol Cancer Res; 2017 Oct; 15(10):1318-1330. PubMed ID: 28710231
[TBL] [Abstract][Full Text] [Related]
34. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function.
Hunter DS; Klotzbücher M; Kugoh H; Cai SL; Mullen JP; Manfioletti G; Fuhrman U; Walker CL
Cancer Res; 2002 Jul; 62(13):3766-72. PubMed ID: 12097287
[TBL] [Abstract][Full Text] [Related]
36. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.
Prizant H; Sen A; Light A; Cho SN; DeMayo FJ; Lydon JP; Hammes SR
Mol Endocrinol; 2013 Sep; 27(9):1403-14. PubMed ID: 23820898
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Chebib N; Archer F; Bobet-Erny A; Leroux C; Cottin V
Sci Rep; 2018 Oct; 8(1):14698. PubMed ID: 30279475
[TBL] [Abstract][Full Text] [Related]
38. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.
Liu F; Lunsford EP; Tong J; Ashitate Y; Gibbs SL; Yu J; Choi HS; Henske EP; Frangioni JV
PLoS One; 2012; 7(6):e38589. PubMed ID: 22719903
[TBL] [Abstract][Full Text] [Related]
39. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
40. Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.
Yue M; Pacheco G; Cheng T; Li J; Wang Y; Henske EP; Schuger L
Am J Pathol; 2016 Jul; 186(7):1825-1836. PubMed ID: 27289491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
